ARTICLE

Assessment and treatment of hypersexuality: a review

Heba Elrafei 🗅 & Qutub Jamali

Heba Elrafei, Acting Consultant, Lancashire & South Cumbria NHS Foundation Trust, Preston, UK. Qutub Jamali, Specialty Doctor, Lancashire & South Cumbria NHS Foundation Trust, Preston, UK. Correspondence Heba Elrafei. Email: Heba.Elrafei@lscft.nhs.uk

First received 20 Dec 2020 Final revision 24 Sep 2021 Accepted 4 Oct 2021

Copyright and usage

© The Author(s), 2021. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists

SUMMARY

Hypersexuality is defined under various terms in the DSM and ICD diagnostic classifications. However, it can be challenging to differentiate between hypersexuality as one of the symptoms of a mental disorder and hypersexual disorder as a primary diagnosis. In this article, we explore the physiology, assessment and treatment of hypersexual disorder, and consider its aetiology and epidemiology. In addition, we highlight the paucity of evidence in the literature about licensed or specific pharmacological recommendations for its treatment and the poor awareness of hypersexuality in clinical and research practice. Further research is recommended to identify more precise guidance for the pharmacological management of hypersexuality.

LEARNING OBJECTIVES:

After reading this article you will be able to:

- make a comprehensive assessment of hypersexual disorders
- describe the current nosological status of this disorder
- understand the currently available treatment options.

KEYWORDS

Hypersexuality; physiology; assessment; management; barriers.

Compulsive behaviours or impulse control disorders such as gambling are now widely recognised (Dhuffar 2016), but hypersexuality remains a controversial symptom or sign. In DSM-5 hypersexuality is defined as 'a stronger than usual urge to have sexual activity' (American Psychiatric Association 2013: p. 823). In ICD-10 (World Health Organization 1992) it is termed 'excessive sexual drive' (F52.7) and subdivided into nymphomania and satyriasis, which may be defined as uncontrollable or excessive sexual desire in women and in men respectively. Various terms are used for this behaviour, such as compulsive sexual disorder, hypersexuality, hypersexual disorder, sexual or sex addiction and Don Juanism, and we use them interchangeably. A particular problem in diagnosis is whether hypersexuality is one of the symptoms of a mental disorder or a condition in itself.

Epidemiology

There is limited literature on the epidemiology of hypersexuality. However, based on older literature, the prevalence of compulsive sexual behaviour is estimated to be 3-6% (Walton 2017). In a survey of 1837 Danish university students, prevalence of compulsive sexual behaviour was reported to be 3% among men and 1.2% among women (Odlaug 2013). A study involving 1913 Swedish young adults reported internet sexual addiction in 2% of women and 5% of men (Ross 2012). Evaluating the prevalence of hypersexual disorder is difficult as study participants may feel embarrassed to report their behaviour (Derbyshire 2015). Hypersexuality has been a controversial issue but some individuals do seek professional help. However, men are more likely to seek help than women (Dhuffar 2016). Dhuffar & Griffiths (2016) found four main barriers explaining women's reluctance to seek help for sex addiction in the UK. They are: (a) individual barriers such as denial and deliberately not wanting to seek treatment; (b) social barriers such as social undesirability and the attitudes of family, parents and peers; (c) research barriers such as lack of universal agreement regarding sexual addiction and limited research into sexual addiction in females; and (d) treatment barriers such as lack of specialist services for the treatment of sexual addiction. However, in 2020, the case of a woman with hypersexuality was reported in a sexually conservative country (Bangladesh) (Arafat 2020), which seems to suggest that there is more widespread awareness now regarding hypersexual behaviour than before.

Aetiological models

Parts of this section report findings explored in Walton et al's (2017) literature review.

Sexual compulsivity

DSM-5 defines compulsions as 'repetitive behaviours or mental acts, the purpose of which is to prevent or reduce personal anxiety or distress, rather than to provide pleasure or gratification'

(American Psychiatric Association 2013). If the increased sexual urge interferes with other important non-sexual goals, then it is not considered as normal sexual behaviour (Howard 2007). Sexual compulsivity may be stress related following trauma (Walton 2017). It could relate to a history of sexual abuse in childhood, which may lead to difficulty in regulating sexual desire, arousal and behaviour and successfully engaging in intimate relationships (Walton 2017). Hypersexual behaviour can be a way of coping with stress and escaping emotionally from painful memories such as rape, war-related trauma or death of a loved one (Walton 2017). Kafka (2010) established that the neurotransmitters involved in compulsive sexual behaviours were monoamines, namely serotonin, dopamine and noradrenaline.

Sexual impulsivity

Sexual impulsivity has been described as the 'inability to resist an impulse, drive or temptation to perform a sexual act that may be personally harmful' (Walton 2017). This includes acting suddenly on a sexual urge with little thought before indulging in the sexual act. Such behaviour is attributed to 'poor impulse control and faulty regulation of sexual motivations' (Walton 2017).

Craving, a symptom of hypersexuality, induces activity mainly in the dorsolateral prefrontal cortex, the ventral striatum, the dorsal anterior cingulate cortex and the amygdala. Hence, these areas, mediated by dopamine, play a significant role in the dependence cycle, which begins by stimulation of dopaminergic neurons in the ventral tegmental region projecting to the nucleus accumbens (the so-called reward centre). This cycle is associated with the repetition of a pulse-like increment in its glutaminergic projections to the prefrontal cortex, which alters brain function and creates neuronal pathways of addictive behaviour (Koob 2016).

Sexual excitation/inhibition

The dual control model of hypersexuality was originally developed to explore the tendency among men for sexual excitation and inhibition (Walton 2017). This led to the development and acceptance of the Sexual Inhibition/Sexual Excitation Scales (SIS/SES) (Walton 2017). Analyses of data from the SIS/SES identified a single sexual excitation factor: sexually arousing situations (for example, seeing an attractive person, watching an erotic video or being aroused by a particular smell); and two types of sexual inhibition: inhibition due to a threat of performance failure (for example, distractions) and inhibition due to the threat of performance consequences (for example, fear of unwanted

pregnancy is said to predict a person's inclination towards sexual arousal) (Walton 2017). People with hypersexuality have been reported to be susceptible to 'higher sexual excitation, lower sexual inhibition due to threat of performance failure and lower sexual inhibition due to the threat of performance consequences compared to the general population' (Walton 2017).

Sex addiction

Early and chronic exposure to graphic cybersexual content can lead to hypersexual behaviour (Walton 2017). In an analysis of a vast amount of internet data, Ogas & Gaddam (2011) estimated that 13% of online searches worldwide were related to erotic content. Analysing data from a survey conducted in 2015-2016 that included 1072 adolescents aged 11-16 across the UK, by Martellozo et al (2020) found that 48% (n = 476) said they had seen online pornography and 52% (n = 525) said they had not. Of those who had seen online pornography, 65% were 15-16 years of age. Martellozo et al compare these findings with the study by the Child Exploitation and Online Protection Command (CEOP), which found that out of 2315 respondents aged 14 to 24, 34% said they had sent a nude or sexual image of themselves to someone they were sexually interested in. The motivations of young people taking and sending sexualised images include sexual gratification (by indulging in online sexual encounters) and sexual exhibitionism with online contacts (Martellozo et al 2020). For some, access to free, anonymous and unrestricted sex chat and pornography websites may lead to repetitive patterns of sexual behaviour that could be difficult to control (Walton 2017). They may become psychologically dependent on the euphoria related to 'feel-good' neurochemicals that are activated with sexual arousal (Walton 2017).

Neurobiology

Neurologically, hypersexual behaviour may be pathological rather than a liking for sex and the individual may feel unable to control their sexual behaviour (Walton 2017). Katehakis (2009) mentions that for some, the experience of emotional disengagement resulting from experiences such as child-hood abuse, attachment-related trauma or neglect during childhood can have a significant impact on their neuropsychobiological development, particularly affecting the central nervous system (CNS), autonomic central nervous system (ANS) and hypothalamic–pituitary–adrenal system (the HPA axis). It is suggested that neurobiological deficits that develop in some of these individuals during early

childhood can adversely affect their emotional and intellectual development, which could potentially cause the onset of sex addiction during adolescence and adulthood (Walton 2017).

In addition, dysfunction in the frontal cortical systems, which are responsible for decision-making and inhibitory control over sexual functioning, may lead to impaired judgement and impulsivity regarding sexual behaviour (Walton 2017). Idiopathic Kleine-Levin syndrome is characterised by recurrent episodes of hypersomnia and behavioural or cognitive disturbances, and some individuals also develop compulsive eating behaviour and hypersexuality (Arnulf 2012). Pathophysiology might involve hypoperfusion in diencephalic structures, especially the thalamus and hypothalamus (Arnulf 2012). Secondary Kleine-Levin syndrome is observed in association with genetic or developmental diseases, stroke or post-traumatic brain haematoma, multiple sclerosis, hydrocephalus, paraneoplastic syndromes, autoimmune encephalitis or severe infections (Arnulf 2012).

Kluver–Bucy syndrome is a rare neuropsychiatric disorder that can occur following traumatic brain injury. Its most common symptom is sexual hyperactivity, and lesion in the amygdala or amygdaloid pathways is considered to be the causative factor. The syndrome is also reported to be associated with destruction or dysfunction of bilateral mesial temporal lobe structures (Clay 2019).

Assessment

In 2009, the Paraphilias Subwork-Group of the DSM-5 Workgroup on Sexual and Gender Identity Disorders proposed that 'hypersexual disorder' should be added as a distinct category in DSM-5, with the diagnostic criteria shown in Box 1. However, DSM-5 rejected the inclusion of hypersexual disorder as a separate category under the overall sexual and gender identity disorders. The reasons mentioned were (Reid 2014):

- lack of scientific research, inadequate neuropsychological testing and potential misuse of new sexual disorder diagnoses by the legal community, particularly in forensic settings where hypersexual disorder would potentially be used as a defence by hypersexual criminal defendants who are being prosecuted for crimes such as child abuse (Halpern 2011);
- hypersexual disorder has no place as a diagnosis but could possibly be an extension of other mental disorders (Halpern 2011).

DSM-5 therefore lacks criteria for diagnosing hypersexuality or compulsive sexual behaviour.

BOX 1 Diagnostic criteria for hypersexual disorder proposed by the DSM-5 Paraphilias Sub-Workgroup

- Over a period of at least six months recurrent and intense sexual fantasies, sexual urges or sexual behaviours in association with three or more of the following five criteria: -
 - Time consumed by sexual fantasies, urges or behaviours repetitively interferes with other important (non-sexual) goals, activities and obligations.
 - Repetitively engaging in sexual fantasies, urges or behaviours in response to dysphoric mood states for example anxiety, depression, boredom or irritability.
 - 3. Repetitively engaging in sexual fantasies, urges or behaviours in response to stressful life events.
 - Repetitive but unsuccessful efforts to control or insignificantly reduce these sexual fantasies, urges or behaviours.
 - Repetitively engaging in sexual behaviours while disregarding the risks for physical or emotional harm to self or others.
- B. There is clinically significant personal distress or impairment in social, occupational or other important areas of functioning associated with the frequency and intensity of these sexual fantasies, urges or behaviours.
- C. These sexual fantasies, urges or behaviours are not due to the direct physiological effect of an exogenous substance for example a drug of abuse or a medication. Specify if:

Masturbation

Pornography

Sexual behaviour with consenting adults

Cybersex

Telephone sex

Strip clubs

Other.

D. The person is ≥18 years of age.

(Published with permission from Kafka (2010))

In ICD-11 (which is scheduled to be implemented in January 2022) hypersexuality is termed 'compulsive sexual behaviour disorder' and defined as follows (see Kraus 2018 for a discussion):

'Compulsive sexual behaviour disorder is characterised by a persistent pattern of failure to control intense, repetitive sexual impulses or urges resulting in repetitive sexual behaviour. Symptoms may include repetitive sexual activities becoming a central focus of the person's life to the point of neglecting health and personal care or other interests, activities and responsibilities; numerous unsuccessful efforts to significantly reduce repetitive sexual behaviour; and continued repetitive sexual behaviour

TABLE 1 Comparison of the proposed diagnostic criteria for hypersexuality in DSM-5 and ICD-11a

DSM-5 diagnosis: hypersexual disorder (proposed for inclusion (Kafka 2010), but proposal rejected by DSM)

ICD-11 diagnosis: compulsive sexual behaviour disorder (World Health Organization 2021)

- I. At least six months of recurrent and intense:
- 1. Sexual fantasies
- 2. Sexual urges
- 3. Sexual behaviours
- A. Along with I, three or more of the following:
- 1. Time consumed by sexual fantasies, urges or behaviours interfering with other important activities.
 - Repeatedly engaging in sexual fantasies, urges or behaviours due to anxiety, depression, boredom or irritability.
 - Repeatedly engaging in sexual fantasies, urges or behaviours in response to stressful life events
- Repeatedly unsuccessful efforts to control or reduce sexual fantasies, urges or behaviours.
- Repeatedly engaging in sexual behaviours ignoring the risks of physical or emotional harm to self or others.
- A. In addition to I, there is clinically significant personal distress or impairment in social, occupational or other important areas of functioning.
- A. Sexual fantasies, urges or behaviours are not due to the direct physiological effect of an exogenous substance for example a drug of abuse or a medication.
- The person is ≥18 years of age.

- I. Persistent pattern of failure to control (six months or more):
- 1. Sexual fantasies
 - 2. Sexual urges
 - 3. Sexual behaviours
- A. Along with I:
- Time consumed by sexual fantasies, urges or behaviours becoming the central focus interfering with other important
 - 2. Repeatedly engaging in sexual fantasies, urges or behaviours despite adverse consequences or deriving little or no satisfaction from it.
 - Repeatedly unsuccessful efforts to control or reduce sexual fantasies, urges or behaviours.
 - Repeatedly engaging in sexual behaviours ignoring the risks of physical or emotional harm to self or others.
- In addition to I, repetitive sexual fantasies, urges or behaviours causes marked distress or significant impairment in personal, family, social, educational, occupational, or other important areas of functioning.
- Distress that is entirely related to moral judgements and disapproval about sexual impulses, urges, or behaviours has to he ruled out

despite adverse consequences or deriving little or no satisfaction from it. The pattern of failure to control intense, sexual impulses or urges and resulting repetitive sexual behaviour is manifested over an extended period of time (e.g., 6 months or more), and causes marked distress or significant impairment in personal, family, social, educational, occupational, or other important areas of functioning. Distress that is entirely related to moral judgments and disapproval about sexual impulses, urges, or behaviours is not sufficient to meet this requirement' (World Health Organization 2021).

The diagnostic criteria proposed by the DSM-5 Paraphilias Sub-Workgroup and those currently set out in ICD-11 are compared in outline in Table 1.

People who present with hypersexuality may also have concurrent anxiety and depression due to the stress of the condition. A case report by Kalra (2013) discusses a depressed man with underlying compulsive sexual behaviour in the form of compulsive frottage. Mina (2019) reports the case of a woman with depression who had a strong impulse to touch men inappropriately, even in the presence of family members.

It is worth noting that before treating hypersexuality the underlying pathology should be clarified. It is therefore crucial to exclude misuse of alcohol and substances (e.g. hallucinogenics, cocaine, amphetamines, propofol anaesthetics) and dopamine agonists treating Parkinsonism, restless leg syndrome and prolactinomas. Mania and hypergonadism should also be ruled out (Thibaut 2018).

Hypersexuality in dementia

The diagnostic criteria for hypersexuality in people with dementia differ from those for hypersexual behaviour in younger adults. Diagnosis depends on the patient's ability to identify the person with whom sexual contact is being initiated and the level of sexual intimacy they would be comfortable with (Series 2005). It also depends on the person's awareness of potential risk of exploitation (Series 2005).

Screening instruments

According to a systematic review by Montgomery-Graham (2017), the Hypersexual Disorder Screening Inventory (HDSI) is the best available screening instrument for hypersexual disorder and its use is recommended in future clinical trials examining the disorder. Other tools identified include the Hypersexual Behavior Inventory, the

a. The proposed DSM-5 criteria are reprinted, with permission, from Kafka (2010). The ICD-11 criteria are reprinted, with permission, from World Health Organization (2021) (will be published in 2022), © World Health Organization 2021.

Compulsivity Scale, the Sexual Addiction Screening Test, the Sexual Addiction Screening Test–Revised, and the Compulsive Sexual Behavior Inventory.

Differential diagnosis

Finlayson et al (2001) designed a decision tree to establish the diagnosis of hypersexual disorder. The first step is to rule out any medical causes. As previously mentioned, hypersexuality has been associated with neurodegenerative conditions such as Parkinson's disease, neurocognitive conditions such as dementia, traumatic brain injury and also the effects of certain drugs, such as dopamine used in dopamine replacement therapy (Callesen 2013). Dopaminergic treatment may reduce sexual inhibition in the cerebral cortex and increase the motivational impulse for seeking sexual stimuli, resulting in hypersexual behaviour (Walton 2017).

The second step is to consider whether hypersexual disorder may be due to substance use (such as cocaine, methamphetamines, alcohol, marijuana and hallucinogens) or medications, as mentioned above.

The third step includes ruling out bipolar disorder or other functional psychotic disorders such as schizophrenia, delusional disorder (erotomania) or any other psychotic disorder.

The fourth step addresses hypersexuality associated with personality disorders. Personality disorders grouped in cluster B, which comprises borderline, antisocial, histrionic and narcissistic personality disorders, are most likely to be associated with hypersexual behaviour (Finlayson 2001). If all these associated disorders are ruled out, the diagnosis of hypersexual disorder could be established.

Treatment

Psychological therapy

Although there is a lack of empirical studies on the efficacy of psychological therapies for hypersexual disorder, the psychotherapy modalities most widely used for the treatment of the disorder are cognitive—behavioural therapy (CBT), psychodynamic psychotherapy, twelve-step or addiction treatment and couples therapy (Kaplan 2010).

A randomised controlled trial of CBT for hypersexual disorder suggested that CBT helps in reducing the sexual compulsivity and also reduces the depressive symptoms associated with the disorder (Hallberg 2019). However, this study included only male participants. The authors recommended encouraging the participation of women in future trials and exploring the administration of online CBT (Hallberg 2019). Acceptance and commitment therapy (ACT) is a form of CBT indicated in hypersexual disorder triggered by problematic internet pornography viewing (Twohig 2010). It emphasises acceptance of thoughts and urges, together with behavioural commitments to engage in therapy and its activities (Twohig 2010). Experiencing sexual urges with acceptance, without acting on them, and while consistently performing self-monitoring can cumulatively lead to refraining from engaging in unwanted sexual behaviours, which in turn would lead to improved self-efficacy (Bandura 2012).

Psychodynamic psychotherapy explores the potential origins of hypersexuality. Fundamental themes include early childhood trauma, shame, avoidance, anger, and impaired self-esteem and self-efficacy (Bergner 2002). It is vital to explore how the person forms and maintains intimate relationships and the meaning of their sexual and romantic behaviour (Montaldi 2002). Psychodynamic therapy would explore the intrapsychic and interpersonal dynamics that underlie the individual's sexual behaviours and fantasies in relation to their history and current relationships, including that with the therapist (Efrati 2019). In addition, it identifies and works through emerging 'therapy-interfering' behaviours that would negatively affect treatment of hypersexuality (Montaldi 2002). Therapy-interfering behaviours could appear to be intentional or unintentional. They include not adhering to the therapy, being flirtatious with the therapist, exhibiting passive or aggressive behaviours and displaying anxious and avoidant tendencies towards the therapist (Chapman 2016).

The twelve-step therapy model helps individuals to hold a sense of responsibility about their behaviour in a safe environment. Treatment goals are focused on helping the individual to stop or control their problematic behaviour, as well as to learn new coping strategies. In treating compulsive sexual behaviour these programmes are usually an adjunct to other modes of therapy (Carnes 2000). Examples of twelve-step self-help programmes include Sex and Love Addicts Anonymous, Sex Addicts Anonymous, Sexaholics Anonymous and Sexual Compulsives Anonymous (Carnes 2000).

Couples therapy may be used to address the suggestion that, for some individuals, hypersexuality could be a reflection of a 'relationship disorder' (Cooper 2003). Dealing with the expectations of each partner in a couple, identifying emotional vulnerabilities, building up trust, honesty and learning skills of intimacy are integral concepts that Brown (1999) highlights for couples therapy. Lasser (2002) describes adaptations to couples therapy from the twelve-step model, underlining that the focus of therapy needs to be redirected to establishing the longer-term pleasure goal of nurturing intimacy rather than depending on the immediate short-term pleasure associated with hypersexuality.

TABLE 2 Some of the drugs that have been used as off-licence treatment of hypersexuality in dementia

Class	Drug	Delivery
SSRIs	Fluoxetine Paroxetine Citalopram	Oral
Antipsychotics	Benperidol Chlorpromazine Risperidone Zuclopenthixol	Oral/i.m.
Anti-androgens	Medroxyprogesterone acetate (MPA) Cyproterone acetate (CPA) Cimetidine	Oral/i.m. Oral/i.m. Oral
Oestrogens	Estrone Estradiol Diethylstilbestrol	Oral/transdermal patches
LHRH analogues	Leuprorelin Triptorelin Goserelin	i.m/s.c.
TCAs	Clomipramine	Oral
Anti-epileptics	Gabapentin	Oral

i.m., intramuscular, LHRH, luteinising hormone-releasing hormone; s.c., subcutaneous. Sources: Series (2005), DeGiorgi & Series (2016).

Relate (the largest provider of relationship support in the UK) and Relationships Scotland have recommended that clinical commissioning groups (CCGs) should improve access to sex therapy services as a part of the National Health Service (NHS) in England (Marjoribanks 2017). Currently this service is not available in all areas of the UK so, depending on their location, some couples may have to fund their treatment themselves. To address the lack of services within the NHS that specifically treat sexual disorders such as hypersexual disorder, Marjoribanks & Bradley (2017) made the following recommendations:

- the sexual relationship support service should be expanded so that it is easily accessible to NHS service users
- policy makers should raise awareness about the sexual health problems and dysfunction and include them in their national health outcome frameworks
- the commissioning of sex therapy services should include evaluation to establish effective evidencebased practice and provide cost-benefit analyses
- front-line health professionals should receive special training about sexual relationships and their impact on health and well-being.

Pharmacological therapy

Most of the medications used in hypersexuality are prescribed off-label (off-licence) and the evidence base on their use is generally weak.

In a 12-week double-blind trial of citalopram (20–60 mg) versus placebo, the outcomes showed significant reduction in libido, masturbation and

pornography use, vet there was no reduction in having many sexual partners (Wainberg 2006). Fluoxetine may also help to improve some features of hypersexuality in men, although there have been no randomised controlled trials of the treatment (National Institute for Health and Care Excellence 2015). Naltrexone has been used as an off-label medication for hypersexuality as it is an inhibitor of endogenous and exogenous opiates and to block dopaminergic release in the nucleus accumbens. It acts on the reward system by blocking the positive reinforcement of addictive behaviour by a mechanism similar to that engaged in the treatment of alcohol and opioid addiction (Verholleman 2020). A number of case reports support the use of variety of other agents, such as naltrexone by itself or in combination with citalopram, clomipramine and valproic acid (Raymond 2002).

Other medications used to treat hypersexuality include mood stabilisers such as lithium and valproate, and antipsychotics used to treat other psychiatric illnesses (e.g. bipolar disorder or psychosis) (Rosenberg 2014). However, it is important to stress that some antipsychotic medications could actually lead to hypersexuality. Aripiprazole, and also clozapine and even risperidone, have been reported to cause hypersexuality themselves (Koener 2007). The mechanism by which aripiprazole could possibly do this is that it is a partial D_2 agonist that works on hypersensitive dopamine receptors; this might lead to a boosted dopamine action in the mesolimbic pathway, favouring the agonist effect of aripiprazole and hence leading to this behaviour (Koener 2007).

In a double-blind controlled study comparing it with chlorpromazine and placebo, benperidol was

MCQ answers 1 d 2 b 3 a 4 a 5 e found to have some 'reducing effect' on libido, in that it participants reported a lower frequency of sexual thoughts (Tennent 1974). Most studies of medication for hypersexuality have included only men, leaving very limited data on effective medications to treat the disorder in women.

Treatment in dementia

Table 2 lists some of the drugs that have been used off-licence to treat hypersexuality in people with dementia.

Research implications

Further research is required to determine the pharmacological treatment of choice for hypersexual disorder. Future clinical trials could focus on treatments to regulate oxytocin levels in addictive behavioural disorders (Lee 2016).

Conclusions

Hypersexual disorder is a very controversial subject. There is sufficient literature available on its clinical presentation, but limited data regarding epidemiology and management. This might be due to barriers to presentation, research and treatment mentioned above in relation to women, but that relevant to men also, which can make the diagnosis very subjective. There have been efforts made in the past to clearly define hypersexual disorder without any overlap with other mental health disorders. DSM-5 rejected the addition of 'hypersexual disorder' as a diagnosis, but ICD-11 has approved its addition, as 'compulsive sexual behaviour disorder'. ICD-11 will be implemented from January 2022. There is insufficient evidence regarding the treatment options available, largely because of the difficulty in recruiting participants to studies. Most small clinical trials done in the past have only included men, thus providing very limited treatment options for women. The key is to acknowledge that hypersexual disorder exists and that more awareness is required. This will facilitate robust clinical trials, which will eventually lead to better clinical outcomes.

Author contributions

H.E. contributed to the aetiology, assessment, treatment, reading objectives and MCQs. Q.J. worked on epidemiology, aetiological model assessment and differential diagnosis. Both authors contributed to the manuscript amendments and submissions.

Funding

None.

Declaration of interest

None.

ICMJE forms are in the supplementary material, available online at https://doi.org/10.1192/bja. 2021.68.

References

American Psychiatric Association (2013) *Diagnostic and Statistical Manual of Mental Disorders* (5th edn) (DSM-5). American Psychiatric Publishing.

Arafat SMY, Kar SJ (2020) Hypersexuality in a Bangladeshi female: a case report. *Journal of Psychosexual Health*, **2**: 93–5.

Arnulf I, Rico TJ, Mignot E (2012) Diagnosis, disease course, and management of patients with Kleine-Levin syndrome. *Lancet Neurology*, 11: 918–28.

Bandura A (2012) On the functional properties of perceived self-efficacy revisited. *Journal of Management*, **38**: 8–10.

Bergner RM (2002) Sexual compulsion as attempted recovery from degradation: theory and therapy. *Journal of Sex & Marital Therapy*, **28**: 373–87.

Brown EM (1999) Affairs: A Guide to Working through the Repercussions of Infidelity. Jossey-Bass.

Callesen MB, Scheel-Kruger J, Kringelbach ML, et al (2013) A systematic review of impulse control disorders in Parkinson's disease. *Journal of Parkinson's Disease*, **3**: 105–38.

Carnes P (2000) Sexual addiction and compulsion: recognition, treatment, and recovery. *CNS Spectrums*, **5**: 63–72.

Chapman AL, Rosenthal MZ (2016) Why people get in their own way. In Managing Therapy-Interfering Behavior: Strategies from Dialectical Behavior Therapy (eds AL Chapman, MZ Rosenthal): 3–17. American Psychological Association. Available from: https://doi.org/10.1037/14752-001.

Clay FJ, Kuriakose A, Lesche D, et al (2019) Kluver-Bucy syndrome following traumatic brain injury: a systematic synthesis and review of pharmacological treatment from cases in adolescents and adults. *Journal of Neuropsychiatry and Clinical Neurosciences*, **31**: 6–16.

Cooper A, Marcus ID (2003) Men who are not in control of their sexual behavior. In *Handbook of Clinical Sexuality for Mental Health Professionals* (eds SB Levine, CB Risen, SE Althof): 311–32. Brunner/Routledge.

DeGiorgi R, Series H (2016) Treatment of inappropriate sexual behavior in dementia. *Current Treatment Options in Neurology*, **18**: 41.

Derbyshire KL, Grant JE (2015) Compulsive sexual behavior: a review of the literature. *Journal of Behavioral Addictions*, **4**: 37–43.

Dhuffar MK, Griffiths MD (2016) Barriers to female sex addiction treatment in the UK. *Journal of Behavioral Addictions*, **5**: 562–7.

Efrati Y, Gerber Z, Tolmacz R (2019) The relation of intra-psychic and relational aspects of the self to compulsive sexual behavior. *Journal of Sex & Marital Therapy*, **45**: 618–31.

Finlayson AJR, Sealey J, Martin PR (2001) The differential diagnosis of problematic hypersexuality. Sexual Addiction & Compulsivity, 8: 241–51.

Hallberg J, Kaldo V, Arver S, et al (2019) A randomized controlled study of group-administered cognitive behavioural therapy for hypersexual disorder in men. *Journal of Sexual Medicine*, **16**: 733–45.

Halpern AL (2011) The proposed diagnosis of hypersexual disorder for inclusion in DSM-5: unnecessary and harmful. *Archives of Sexual Behavior*, **40**: 487–8.

Howard MD (2007) Escaping the pain: examining the use of sexually compulsive behavior to avoid the traumatic memories of combat. *Sexual Addiction & Compulsivity*, **14**: 77–94.

Kafka MP (2010) Hypersexual disorder: a proposed diagnosis for DSM-V. Archives of Sexual Behavior, 39: 377–400.

Kalra G (2013) The depressive façade in a case of compulsive sex behavior with frottage. *Indian J Psychiatry*, **55**: 183–5.

Kaplan MS, Krueger R (2010) Diagnosis, assessment and treatment of hypersexuality. *Journal of Sex Research*, **47**: 181–98.

Katehakis A (2009) Affective neuroscience and the treatment of sexual addiction. Sexual Addiction & Compulsivity, 16: 1–31.

Koener B, Hermans E, Maloteaux JM, et al (2007) Paradoxical motor syndrome following a switch from atypical neuroleptics to aripiprazole. *American Journal of Psychiatry*, **164**: 1437–8.

Koob GF, Volkow ND (2016) Neurobiology of addiction: a neurocircuitry analysis. *Lancet Psychiatry*, **3**: 760–73.

Kraus SW, Krueger RB, Briken P, et al (2018) Compulsive sexual behaviour disorder in the ICD-11. World Psychiatry, 17: 109–10.

Lasser MR (2002) Recovery for couples. In *Clinical Management of Sex Addiction* (eds PJ Carnes, KM Adams): 125–36. Brunner/Routledge.

Lee MR, Rohn MC, Tanda G, Leggio L (2016) Targeting the oxytocin system to treat addictive disorders: rationale and progress to date. *CNS Drugs*, **30**: 109–23.

Marjoribanks D, Bradley AD (2017) Let's Talk About Sex: The State of Our Sexual Relationships in the UK Today. Relate (https://www.relate.org.uk/sites/default/files/the_way_we_are_now_-_lets_talk_about_sex_0.pdf).

Martellozo E, Monaghan A, Davidson J, et al (2020) Researching the affects that online pornography has on U.K. adolescents aged 11 to 16. *SAGE Open*, **10**(1): 1–11.

Mina S (2019) Compulsive sexual behavior in depressed women. *Indian Journal of Psychiatry*, **61**: 541–3.

Montaldi DF (2002) Understanding hypersexuality with an Axis II model. *Journal of Psychology & Human Sexuality*, 14: 22–3.

Montgomery-Graham S (2017) Conceptualization and assessment of hypersexual disorder: a systematic review of the literature. *Sexual Medicine Reviews*, **5**: 146–62

National Institute for Health and Care Excellence (2015) *Hypersexuality:* Fluoxetine. Evidence Summary. NICE (nice.org.uk/guidance/esuom46).

Odlaug BL, Lust K, Schreiber LR, et al (2013) Compulsive sexual behavior in young adults. *Annals of Clinical Psychiatry*, **25**: 193–200.

Ogas O, Gaddam S (2011) A Billion Wicked Thoughts: What the World's Largest Experiment Reveals about Human Desire. Dutton.

Raymond NC, Grant JE, Kim SW, et al (2002) Treatment of compulsive sexual behaviour with naltrexone and serotonin reuptake inhibitors: two case studies. *International Clinical Psychopharmacology*, 17: 201–5.

Reid R, Kafka MP (2014) Controversies about hypersexual disorder and the DSM-5. *Current Sexual Health Reports*, **6**: 259–64.

Rosenberg KP, Carnes P, O'Connor S (2014) Evaluation and treatment of sex addiction. *Journal of Sex & Marital Therapy*, **40**: 77–91.

Ross MW, Mansson SA, Daneback K (2012) Prevalence, severity and correlates of problematic sexual internet use in Swedish men and women. Archives of Sexual Behavior, 41: 459–66.

Series H, Dégano P (2005) Hypersexuality in dementia. Advances in Psychiatric Treatment, 11: 424-31.

Tennent G, Bancroft J, Cass J (1974) The control of deviant sexual behavior by drugs: a double-blind controlled study of benperidol, chlorpromazine, and placebo. *Archives of Sexual Behaviour*, **3**: 261–71.

Thibaut F (2018) Incorporating pharmacological treatment strategies. In *Routledge International Handbook of Sexual Addiction* (eds T Birchard, J Benfield): 282–92. Taylor and Francis.

Twohig MP, Crosby JM (2010) Acceptance and commitment therapy as a treatment for problematic internet pornography viewing. *Behavior Therapy*, **41**: 285–95.

Verholleman A, Victorri-Vigneau C, Laforgue E, et al (2020) Naltrexone use in treating hypersexuality induced by dopamine replacement therapy: impact of OPRM1 A/G polymorphism on its effectiveness. *International Journal of Molecular Sciences*. 21: 3002.

Wainberg ML, Muench F, Morgenstern J, et al (2006) A double-blind study of citalopram versus placebo in the treatment of compulsive sexual behaviors in gay and bisexual men. *Journal of Clinical Psychiatry*, **67**: 1968–73.

Walton MT, Cantor JM, Bhullar N, et al (2017) Hypersexuality: a critical review and introduction to the "sexhavior cycle". *Archives of Sexual Behavior*, **6**: 2231–51.

World Health Organization (1992) *The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guideline.* WHO

World Health Organization (2021) *ICD-11 for Mortality and Morbidity Statistics (ICD-11 MMS) (version: 05/2021).* WHO (https://icd.who.int/browse11/l-m/en).

MCQs

Select the single best option for each question stem

- 1 Concerning the pathophysiology of hypersexuality, which one of the following is incorrect:
- a organic brain lesions could present with hypersexuality
- b Kleine–Levin syndrome presents with hypersomnia along with hypersexuality
- c oxytocin signaling pathway is involved/implicated in the pathogenesis of hypersexuality
- d monoamines are not associated with hypersexual behaviour
- **e** emotional detachment could be one of the contributing factors to sexual addiction.

- 2 Concerning the epidemiology and diagnosis of hypersexuality:
- a women are more likely to seek help than men
- b there is more awareness about hypersexuality than in the past
- c ICD-10 includes hypersexuality as a separate diagnostic entity
- d the prevalence of hypersexuality in adults is estimated to be 6%
- e nymphomania is known in males.
- 3 Hypersexuality:
- a may be associated with a sudden surge in glutamate in the prefrontal cortex
- **b** is neither an impulsive nor a compulsive behaviour
- **c** is not associated with early exposure to cyberporn
- d does not affect the individual's life or functioning
- $\boldsymbol{e}\$ is rarely associated with any risk behaviour.

- 4 ICD-11:
- a includes hypersexuality as a sole diagnosis (compulsive sexual behaviour disorder)
- **b** includes hypersexuality only as a part of other diagnoses
- c declined to include hypersexuality as either a symptom or a disorder
- d does not include indulging in repetitive sexual activities as a pivotal criterion for diagnosing hypersexuality
- gives 18 years as the minimum age for diagnosing hypersexuality.
- 5 Psychological therapies that work in treatment of hypersexuality are:
- a psychodynamic therapy
- b cognitive-behavioural therapy
- c twelve-steps (addiction) treatment
- d acceptance and commitment therapy
- e all of the above.